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X-linked myotubular myopathy is a severe congenital
myopathy caused by deficiency of the lipid phospha-
tase, myotubularin. Recent studies of human tissue and
animal models have discovered structural and physio-
logical abnormalities in myotubularin-deficient muscle,
but the impact of myotubularin deficiency onmyogenic
stem cells within muscles is unclear. In the present
study, we evaluated the viability, proliferative capacity,
and in vivo engraftment of myogenic cells obtained
from severely symptomatic (Mtm14) myotubularin-de-
ficient mice. Mtm14 muscle contains fewer myogenic
cells thanwild-type (WT) littermates, and the number of
myogenic cells decreases with age. The behavior of
Mtm14 myoblasts is also abnormal, because they en-
graft poorly into C57BL/6/Rag1null/mdx5cv mice and
display decreased proliferation and increased apoptosis
compared with WT myoblasts. Evaluation of Mtm14
animals at 21 and 42 days of life detected fewer satellite
cells in Mtm14 muscle compared with WT littermates,
and the decrease in satellite cells correlated with pro-
gression of disease. In addition, analysis of WT and
Mtm14 regeneration after injury detected similar ab-
normalities of satellite cell function, with fewer satellite
cells, fewer dividing cells, and increased apoptotic cells
in Mtm14 muscle. These studies demonstrate specific
abnormalities in myogenic cell number and behavior
that may relate to the progression of disease in myotu-bularin deficiency, and may also be used to develop in
vitro assays by which novel treatment strategies can be
assessed. (Am J Pathol 2012, 181:961–968; http://dx.doi.
org/10.1016/j.ajpath.2012.05.016)
X-linked myotubular myopathy (XLMTM) is a severe form of
congenital myopathy with an estimated incidence of
1:50,000 male births that most often presents with severe
perinatal weakness and respiratory failure.1–3 XLMTM is
caused by mutations in the MTM1 gene that encodes a
phosphoinositide phosphatase called myotubularin. Myotu-
bularin plays a role in multiple cellular processes, including
endosomal trafficking,4 excitation contraction coupling,5–7
intermediate filament organization,8 and apoptosis.9 Muscle
biopsy specimens from patients with XLMTM display ex-
cessively small fibers with increased numbers of central
nuclei and aggregation of organelles within the central re-
gions of many cells.3 A murine model of myotubularin defi-
ciency, theMtm14mouse [also referred to asMtm1 knock-
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the human disease, including severe weakness, respiratory
failure, and histological findings that includemyofiber small-
ness and increased numbers of centrally nucleated fi-
bers.11 Whether the myofiber smallness might be due to
poor function of satellite cells and/or other myogenic pro-
genitors remains unclear.
To identify whether there was an easily testable pheno-
type in myotubularin-deficient myoblasts, we used
fluorescence-activated cell sorting (FACS) to isolate pro-
spective myogenic cell fractions from Mtm14 and wild-
type (WT) animals and assessed proliferation, apoptosis,
fusion, and engraftment of these cells. Muscle from 25- to
30-day-old Mtm14 mice had a consistently increased
number of cells in the stem cell antigen (SCA)1, CD45,
platelet-derived growth factor receptor (PDGFR) , and
propidium iodide (quadruple-negative) population com-
pared with their WT littermates. In contrast, the number of
CD31, CD45, CD106 [vascular cell adhesion molecule
1 (VCAM1)] myogenic cells, and evaluations of Pax7 ex-
pression, revealed decreased numbers of satellite cells in
Mtm14 mice that progressed with age.Mtm14 myoblasts
also displayed increased apoptosis, slow proliferation, and
poor engraftment compared with WT myoblasts. This cor-
responded to increased apoptosis, decreased proliferation,
and reduced numbers of Pax7 satellite cells after cardio-
toxin injection, as well as a progressive decrease in the num-
ber of Pax7 satellite cells with the progression of disease, in
Mtm14 mice. These functional abnormalities in myogenic
cells can partially explain the inevitable decline of Mtm14
muscles, and they provide reproducible and potentially test-




All studies were fully approved by the Institutional Animal
Care and Use Committee at Children’s Hospital Boston
(Boston, MA). Mtm1/C57BL/6 (Mtm14) mice were bred
and genotyped as previously described.12 Cell transplan-
tation studies used dystrophin-deficient 5- to 6-month-old
immunocompromised C57BL/6 Rag1null mdx5cv mice,
which were custom generated at the Jackson Laboratory
(Bar Harbor, ME) by crossing mdx5cv mice with Rag1-null
mice.
Myoblast Isolation and FACS
Quadruple-Negative Cells
Primary muscle cells were dissected and dissociated in
parallel from the upper and lower limbs of Mtm14 and WT
littermate mice between 25 and 30 days of life (DOL) fol-
lowing established methods.13,14 Cells were incubated on
ice with fluorescein isothiocyanate–conjugated anti-Ly-
6A/E (SCA-1, clone E13-161.7; BD Biosciences, San Jose,
CA), phosphatidylethanolamine-Cy5–conjugated anti-
CD45 (clone 30F11; BD Biosciences), and APC-conjugated
anti-CD140a (PDGFR, clone APA5; BioLegend, San Diego,CA) antibodies and propidium iodide (SigmaAldrich, St Louis,
MO) for 45minutes.Cellswere thenanalyzedandsortedusing




Primary muscle cells were dissociated from Mtm14
and WT mice at 45 to 49 DOL, as previously described.
The antibodies used for FACS analysis included fluores-
cein isothiocyanate–conjugated anti-CD31 antibody
(clone 390; BD Biosciences), phosphatidylethanolamine-
conjugated anti-CD45 (clone 30-F11; BD Biosciences),
and APC-conjugated CD106 (clone 429; BioLegend).
Proliferation Assays
Quadruple-negative cells from 25- to 30-day-old WT or
Mtm14 mice were plated onto 96-well plates at a density
of either 1000, 5000, or 10,000 cells per well in Human
Skeletal Muscle Growth Media (Promocell, Heidelberg,
Germany). Proliferation was measured at 0, 2, and 4 days
after isolation using a CellTiter 96 AQueous Non-Radio-
active Cell Proliferation Assay (number TB169; Promega,
Madison, WI), per manufacturer’s instructions. Absor-
bance was read at 490 nm using a Synergy 2 plate
reader (Biotek Instruments, Winooski, VT). The average of
three wells for each condition was recorded for each time
point, data were standardized by comparing the values
from WT with Mtm14 cells from each individual animal
pair, and the entire experiment was repeated three times.
Statistical differences between corrected values were
compared using a two-way analysis of variance.
Caspase Assays
After FACS, 250,000 quadruple-negative cells from 25- to
30-day-old WT or Mtm14 mice were plated onto a 10-cm
collagen-coated culture dish in Human Skeletal Muscle
Growth Media (Promocell). Three aliquots of 100,000 qua-
druple-negative cells were also frozen as a time  0 con-
dition. After 2 or 4 days in culture, three aliquots of 80,000
cells were frozen at80°C. Apoptosis was evaluated using
a Caspase-Glo 3/7 Assay kit (Promega), following the man-
ufacturer’s instructions, and read on a single-tube luminom-
eter (Berthold Instruments, Oak Ridge, TN). Statistical dif-
ferences between corrected values were compared using a
two-way analysis of variance. Depending on cell yields
available from each animal, between 1 and 3 replicates at
each time point were performed on each animal cell isolate,
using five different animal isolates for each genotype.
Fusion Assays
Primary myogenic cells from 25- to 30-day-old WT or
Mtm14 mice were enriched using the preplating tech-
nique.15 Myogenic cells were cultured on Matrigel-
coated plates in Dulbecco’s modified Eagle’s medium
(DMEM) high glucose supplemented with 30% fetal bo-
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factor. For fusion assays, 10,000 cells per well were
plated in eight-well permanox slides coated with Matrigel.
Cells adhered overnight in high serum medium, then
switched to differentiation medium (DMEM low glucose
supplemented with 4% FBS). Differentiation medium was
changed daily, and fusion was assessed at days 0, 2,
and 5 after the induction of differentiation. Cells were
fixed and stained with a rabbit monoclonal anti-desmin
antibody (Epitomics) diluted 1:100. The percentage of
fused cells was calculated using 10 randomly photo-
graphed fields for each animal. Data were collected from
three animals per genotype. Alternatively, quadruple-
negative cells from 25- to 30-day-old WT orMtm14 mice
were plated onto gelatin in a 48-well culture plate at
50,000 cells per well in DMEM High Glucose plus 20%
FBS and 3 g/mL basic fibroblast growth factor (Invitro-
gen, Carlsbad, CA). Media were changed every 2 days
until the cultures reached 70% confluence, and then me-
dia were changed to DMEM Low Glucose (Invitrogen)
plus 2% FBS to promote differentiation. Media were
changed daily for 3 days. After methanol fixation, immu-
nohistochemical (IHC) staining was performed using
standard techniques, with anti-human desmin primary
antibodies (1:100, M0760; Dako, Carpentaria, CA) and
AlexaFluor 568–conjugated goat anti-mouse IgG sec-
ondary antibodies (Invitrogen). Slides were coverslipped
in Vectashield Hard Set mounting media containing DAPI
(Vector Laboratories, Burlingame, CA) and evaluated us-
ing a Nikon TE-2000S microscope (Nikon, Melville, NY).
The fusion index in control and myotubularin-deficient
culture cells was calculated as the ratio of fused nuclei
within myotubes/number of total nuclei. Fusion indices
were compared in control and mutant cultures using the
Student’s t-test. These studies were performed using
myoblasts isolated from two different mice of each geno-
type and two to three replicates performed per mouse,
depending on cell yields.
FDB Preparations
Flexor digitorum brevis (FDB) muscles from 25- to 30-
day-old WT or Mtm14 mice were extracted using stan-
dard techniques16,17 and plated on laminin-coated
chamber slides. After incubating for 6 hours in DMEM
with 10% FBS, cultured fibers were fixed in paraformal-
dehyde and stained for Pax7 (Developmental Studies
Hybridoma Bank, Iowa City, IA) and DAPI using standard
IHC techniques.16 Data were quantified as the number of
fibers containing satellite cells per 100 fibers evaluated.
The number of nuclei per fiber was nearly identical when
comparing WT with KO cultures within the images quan-
tified.
Western Blot Analysis
Quadruple-negative cells were pelleted and then lysed
using MPER buffer (Thermo Scientific, Waltham, MA)
containing protease and phosphatase inhibitors at a con-
centration of 1 L per 10,000 cells isolated. Western blot
procedures were performed as previously described.18Transferred proteins were probed with antibodies against
Pax7 (Developmental Studies Hybridoma Bank) and
glyceraldehyde-3-phosphate dehydrogenase (6C5; Ab-
cam, Cambridge, MA) and visualized using enhanced
chemiluminescence. Quantification of protein levels nor-
malized to glyceraldehyde-3-phosphate dehydrogenase
was performed with the program Quantity One version
4.2.1 (Bio-Rad Laboratories), on an Image Station 440
(Kodak DS).
Pax7 mRNA Expression
Total RNA was purified from frozen muscles using TRIzol
reagent (Invitrogen), according to manufacturer’s instruc-
tions, treated with DNase, and reverse transcribed using
Super Script II RNase H Reverse Transcriptase (Invitro-
gen) in the presence of Random Primers (Promega).
Real-time PCR was performed using an ABI Prism 7900
apparatus (Applied Biosystems, Foster City, CA) at 60°C
as the melting temperature, with the following primers:
ribosomal protein large P0, 5=-CTCCAAGCAGATGCAG-
CAGA-3= and 5=-ATAGCCTTGCGCATCATGG-3=; and
Pax7 (paired-box gene 7), 5=-GGAAACCAGTGTGC-
CATCT-3= and 5=-CCTTGTCTTTGGCACCATTT-3=.
Cell Transplantation
Quadruple-negative cells from WT and Mtm14 donor
mice cells were pelleted and resuspended in 1.2% bar-
ium chloride (Sigma Aldrich). The tibialis anterior (TA)
muscles of isoflurane-anesthetized, 5- to 6-month-old
C57BL/6 Rag1null mdx5cv mice were injected with a 10-
to 15-L suspension containing 50,000 cells. Mice were
sacrificed 1 month after injection, and the TA muscles
were frozen in isopentane for histological analysis. Cryo-
sections (8-m thick) were cut and stained for dystrophin
(ab15277; Abcam) and DAPI at 80-m intervals to eval-
uate dystrophin expression related to engraftment. Sec-
tions with the maximum number of positive fibers for a
given muscle were photographed and counted. The max-
imum number of positive fibers in a given section was
quantified for TA muscles injected with WT (n  4) and
KO (n  8) cells, and compared using the Student’s
t-test. Additional cryosections (8-m thick) were stained
with H&E or Gomori trichrome to histologically evaluate
the engraftment sites, as described later.
Cardiotoxin Injection
The right TA muscle of three isoflurane-anesthetized WT
or Mtm14 mice at 28 DOL were injected with 15- to
20-L cardiotoxin (Sigma Aldrich) diluted at a final con-
centration of 0.5 g/L in sterile PBS. At 5 to 6 days after
injection, the animals were euthanized and the TA mus-
cles were extracted and snap frozen in isopentane.
Tissue Histological Data
Cross sections (8 m thick) of isopentane–frozen TA or
quadriceps muscle were taken midway down the length
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trichrome using standard techniques. IHC for Ki-67, a
marker of cellular proliferation, was performed on TA
muscles of cardiotoxin-injected animals by standard IHC
techniques using Ki-67 primary antibody (ab16667; Ab-
cam) and biotinylated horse anti-rabbit IgG (Vector Lab-
oratories). TUNEL staining was performed on these mus-
cles using an In Situ Cell Death Detection Kit POD
(Roche, Indianapolis, IN), per the manufacturer’s instruc-
tions. IHC for Pax7 was performed on TA muscles from
cardiotoxin-injected animals and on quadriceps muscles
from three uninjured WT and three Mtm14 at 21 and 42
DOL after fixation of slides in 4% paraformaldehyde,
blocking with both H2O2 and unconjugated Donkey Anti-
Mouse IgG Fab Fragment (Jackson ImmunoResearch,
West Grove, PA) in 1% bovine serum albumin, and ex-
posure to Pax7 primary antibody (Developmental Studies
Hybridoma Bank) and biotin-SP-conjugated donkey anti-
mouse IgG Fab fragment (Jackson ImmunoResearch)
secondary antibodies. Light microscopic images were
captured using an Olympus DP72 camera and cellSens
Standard software (Olympus, Center Valley, PA). Images
were quantified by counting the number of positive cells
within a field and dividing by the total number of fibers
(for Pax7 and TUNEL) or nuclei (for Ki-67) within that field.
Results
To enrich for myogenic cells using FACS, our primary
approach was to purify myogenic cells that were quadru-
ple negative for SCA1, CD45, PDGFR, and propidium
iodide. SCA1 labeled most nonmyogenic cells in skeletal
muscle,19–21 although rare SCA1-expressing myogenic
cells were also reported.22–24 CD45 labeled immune
cells, PDGFR was a fibroadipogenic cell marker,25,26
and propidium iodide was a marker of dead cells. Pooled
limb muscles isolated from 26- to 30-day-old Mtm14
mice and their WT male littermates consistently showed
more quadruple-negative cells in Mtm14 tissue (P 
0.01, n  5), despite much higher tissue yields from the
WT littermates (Figure 1A). Fusion assays revealed many
desmin-expressing myoblasts and myotubes in both WT
and Mtm14 cultures, which confirmed that our sorting
strategy enriched cultures for myogenic cells (Figure 1B).
When areas of equivalent cellularity were quantified in WT
and Mtm14 myogenic cell cultures, the fusion index did
not significantly vary between WT and Mtm14 cultures
(Figure 1B).
We further investigated the myogenic cell populations
in Mtm14 mice by evaluating the expression of Pax7, a
marker of satellite cells, at the quiescent or early acti-
vated stage, in the quadruple-negative populations, and
in isolated myofibers. When evaluating Pax7 expression
per 200,000 cells, quadruple-negative Mtm14 cells
showed significantly decreased levels of Pax7 (36% 
11% of WT values) expression (Figure 1C). Similarly, im-
munostaining for Pax7 satellite cells in cultured FDB
fibers revealed that the number of Pax7 satellite cells in
Mtm14 FDBs (47.76  10.0 fibers containing Pax7cells per 100 fibers evaluated) was significantly lowerthan in WT FDBs (78.62  8.16 fibers containing Pax7
cells per 100 fibers evaluated) isolated from 26- to 30-
day-old animals (Figure 2A). These findings suggested
that the number of satellite cells in Mtm14 animals was
decreased compared with WT littermates, despite more
quadruple-negative cells in Mtm14 mice.
We further evaluated the number of prospective satellite
cells in WT and Mtm14 mice by using a different FACS
strategy to isolate CD31, CD45, CD106 (Vcam-1)
cells.27 This strategy revealed thatMtm14 animals at 45 to
49 DOL had significantly fewer Vcam-1 satellite cells com-
pared with age-matched littermates (Figure 2B), further
suggesting an age-related decrease in myogenic cells in
Mtm14 mice.
To evaluate the relationship between satellite cell num-
ber and progression of disease, Pax7 immunostaining
was performed on quadriceps muscles from Mtm14 an-
imals at 21 and 42 DOL (Figure 3A). These studies de-
tected significantly fewer satellite cells when comparing
Mtm14 muscle with age-matched WT animals. In addi-
tion, there was a significant decrease in the number of
satellite cells found when comparing Mtm14 animals at
21 and 42 DOL, confirming a marked decrease in the
satellite cell population with the progression of disease.
This finding was also confirmed through the evaluation of
Pax7 mRNA levels at 14, 21, and 30 DOL in the Mtm14
Figure 1. Properties of quadruple-negative cells. A: FACS of 25- to 30-day-
old WT and Mtm14 (KO) pooled limb muscles for SCA1, PDGFR,
CD45, and propidium iodide (ie, quadruple-negative) cells reveals that
Mtm14 mice possess significantly more quadruple-negative cells compared
with WT littermates. P  0.01. B: Immunostaining for desmin during a fusion
assay confirms the myogenic potential of these cells and reveals similar
fusion indices in equivalently populated regions of WT and Mtm14 (KO)
cell cultures. C: Western blot analyses performed on lysates of freshly sorted
quadruple negative cells reveal decreased levels of Pax7 in Mtm14 (KO)
animals. *P  0.05. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.TA muscle (Figure 3B). Pax7 mRNA expression was de-
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addition, there was a significant decrease in Pax7 mRNA
expression when comparing Mtm14 animals at 14 and
30 DOL, consistent with the progression-related de-
crease in satellite cells observed in our IHC studies.
Although a decline in Pax7 expression was evident
in Mtm14 animals, quadruple-negative cells displayed
myogenic activity in vitro and equal fusion capacity to WT
cells. To determine whether myotubularin-deficient myo-
genic progenitors had the ability to function in a myotubu-
larin-competent environment in vivo, we transplanted qua-
druple-negative cells from either Mtm14 or WT mice at 25
to 30 DOL into the TA muscles of dystrophin-deficient
C57BL/6 Rag1null mdx5cv mice and evaluated dystrophin
expression 1 month after transplantation. Mdx5cv mice
were used in this assay because they displayed approxi-
mately 10-fold less revertant fibers compared with mdx
mice.28 H&E and Gomori trichrome staining of implanted
muscles showed no differences between muscles injected
with WT orMtm14 cells. On IHC evaluation for dystrophin-
positive fibers, which are an indicator of the successful
engraftment of transplanted myogenic cells, Mtm14 cells
showed a dramatically decreased amount of engraftment
(9.0  3.8 dystrophin-positive fibers) compared with WT
cells (38.5  8.1 dystrophin-positive fibers), despite being
transplanted at equivalent cell numbers (Figure 4A). Al-
though this technique was unable to distinguish between
engrafted and revertant fibers, there were fewer than nine
dystrophin-positive fibers in six of the eight Mdx5cv mus-
cles injected with Mtm14 cells. These results suggested
that the revertant fibers compose a minority of the dystro-
phin-positive fibers observed after the injection of Mdx5cv
muscles with WT cells.
These engraftment findings suggested that Mtm14
Figure 2. Decreased expression of Pax7 and number of prospective satellite cells
are found in myotubularin-deficient muscle. A: Pax7 immunostaining of FDB fibers
reveals fewer fibers containing Pax7 nuclei in myofibers isolated from Mtm14
(KO) animals. *P 0.05.B: FACS of 45- to 49-day-oldWT andMtm14 (KO)mouse
muscle for CD31CD45CD106 (Vcam1 myogenic cells) reveals a depletion of
this population in Mtm14 muscle. P  0.05. SSC, side scatter.myogenic cells may be impaired with respect to survivaland/or function. To address this, cell proliferation and apop-
tosis assays were performed. Quadruple-negative cells
from 25- to 30-day-old Mtm14 mice displayed decreased
proliferation (51% to 70% of WT values, P  0.05) immedi-
ately after sorting, but the difference in proliferation in WT
and Mtm14 animals was less pronounced (KO  36% to
87% of WT values, P  ns) by 4 days after isolation (Figure
4B). Apoptosis after isolation was also measured using
caspase-3 and caspase-7 activity, because abnormalities
of the caspase apoptotic pathway and increased apoptosis
were reported in myotubularin knockdown studies using
HeLa cells.9 Caspase-3 and caspase-7 activity was in-
creased in Mtm14 cells at 0, 2, and 4 days after isolation
(178%, 151%, and 266% of WT levels, respectively; P 
0.05), consistent with persistently increased apoptosis in
Mtm14 myogenic cells (Figure 4C). Collectively, our find-
Figure 3. Depletion of satellite cells with progression of disease in Mtm14
muscle. A: Immunostaining results for Pax7 in the quadriceps muscles of WT
andMtm14 (KO) mice at 21 and 42 DOL are quantified to evaluate the satellite
cell populations in vivo. Arrows indicate Pax7-positive nuclei in WT and KO
animals. B:mRNA levels of 14-, 21-, and 30-day-old mice (n 9) are quantified
by quantitative RT-PCR, normalized to the ribosomal protein large P0 mRNA
level, and compared with WT. Scale bar  20 m. *P  0.05.
apoptos
*P  0.0
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plantation of myoblasts from Mtm14 mice was likely be-
cause of impairment of myogenic cell survival and
proliferation, rather than abnormalities related to cell fusion.
The in vivo relevance of our findings was addressed
through evaluation of the healing process and the baseline
Pax7 satellite cell levels in Mtm14 and WT mice. Five
days after injection of the TA muscles of Mtm14 mice with
cardiotoxin, which produces a focal muscle injury and stim-
ulates satellite cell activation, proliferation, and differentia-
tion, Mtm14 and WT muscle showed similar degrees of
fiber regeneration and response to injury (Figure 5). Unin-
jured TA muscles showed pathological characteristics typ-
ical of myotubularin-deficient muscle, including marked fi-
ber size variation and myofiber smallness in the absence of
endomysial fibrosis, myonecrosis, or inflammation. Centrally
nucleated fibers, which were less commonly seen in
Mtm14 mice, compared with other murine29 and canine30
models of myotubularin deficiency, were not significantly
increased in the uninjured TA muscles at this time point
(Figure 5). Regenerating areas in injured TA muscles were
readily identifiable by the presence of numerous centrally
nucleated fibers, surrounded by a mixed population of
mononuclear cells composed of satellite cells, macro-
Figure 4. Poor survival of myotubularin-deficient cells in vivo and vitro. A:
TA muscles of C57BL/6 Rag1null mdx5cv mice, staining for dystrophin (D
engrafted fibers after transplantation of Mtm14 (KO) cells (n  8) compared
by counting the highest number of dystrophin-expressing fibers within a sing
entire TA muscle. Top panels: H&E and trichrome stains of the injection sit
which correlates with proliferation, is markedly higher in freshly isolated W
difference in proliferation after 4 days in culture. MTS, 3-(4,5-dimethylthiazol-
phenazine methosulfate. C: A caspase-3/caspase-7 assay, which measures
activation in Mtm14 (KO) cells after FACS and at 2 and 4 days in culture.phages, and lymphocytes. Although mild fibrosis, interstitialedema, and an increase in the number of small blood ves-
sels were noted on H&E and Gomori trichrome stains, these
findings were present to an equivalent extent in regenerat-
ing WT andMtm14 muscles. On immunostaining for Pax7,
Ki-67, and apoptotic cells (using a TUNEL assay), however,
differences in the response to injury in WT and Mtm14
mice became apparent. After injury, Mtm14 muscle con-
tained fewer satellite cells, fewer proliferative cells, and
more apoptotic cells than WT muscle (Figure 5). Although
not all of the proliferating and apoptotic cells might corre-
spond to satellite cells, these data provided in vivo evidence
for abnormal satellite cell behavior in Mtm14 animals, in-
volving abnormal levels of both proliferation and apoptosis.
Discussion
Several studies have been conducted on myotubularin-de-
ficient cells in the past. Studies performed on myotubes
from human patients reported normal cytoskeletal develop-
ment, fusion, and behavior,31,32 but proliferation, apoptosis,
and engraftment were not evaluated. More recent work on
Mtm14 cells, cells with myotubularin knockdown, HeLa,
and primary human cells, however, has revealed that myo-
onth after transplantation of freshly sorted quadruple-negative cells into the
bottom panels) and DAPI (blue) reveals significantly fewer successfully
T cells (n  4). *P  0.01. Quantification of dystrophin fibers is performed
on of the entire TA muscle after surveying sections every 80 m through the
ng little or no fibrosis from the injected cells. B: Incorporation of MTS/PMS,
compared with cells from Mtm14 (KO) littermates. There is no significant
3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; PMS,
is through the activation of caspase-3/caspase-7, reveals increased caspase






2-yl)-5-(tubularin-deficient cells show abnormalities of cytoskeletal
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unable to detect abnormalities in desmin expression or cy-
toskeletal organization in cultured myoblasts and myotubes
while staining for desmin in fusion assays, the techniques
we used were not nearly as sensitive as those described by
Hnia et al.8 We were, however, able to demonstrate the
presence of increased apoptosis in primary myotubularin-
deficient myoblasts through increased activation of
caspase-3 and caspase-7, consistent with the results re-
ported in myotubularin-deficient cells.9
Abnormalities in the number and behavior of myogenic
cells were also noted in Mtm14 muscle. Although there
were more quadruple-negative cells in Mtm14 animals
compared with WT littermates, further investigation by
FACS, IHC, gene expression, and Western blot analysis
revealed that Pax7 expression is consistently decreased
when comparingMtm14 with WT cell fractions and muscle
tissue. In addition, data from these studies indicate that the
number of myogenic cells markedly decreases with the
progression of disease in Mtm14 mice. Our findings sug-
gest that such depletion may occur through both slow pro-
liferation and increased apoptosis of these myogenic cells.
Depletion of satellite cells has been described in mice and
humans deficient for dystrophin33,34 and selenoprotein N35
and in models of aging36 and denervation.37 Although this
finding is nonspecific, it provides evidence for an additional
degenerative component of the muscle dysfunction seen in
myotubularin deficiency.
As an enzyme involved in sarcotubular and myofibrillar
organization, endosomal trafficking, and excitation contrac-
tion coupling,6–8 myotubularin may affect cell survival path-
ways through several mechanisms. Pathways involved in
the induction of apoptosis include the activation of deathreceptors,38 the release of apoptogenic factors from mito-
chondria,39 and the unfolded protein response produced
as the result of the accumulation of misfolded proteins in the
endoplasmic reticulum.40 Abnormalities in intracellular cal-
cium produced in myotubularin deficiency7 may cause mi-
tochondrial stress and activation of the mitochondrial apop-
totic pathway. Alternatively, abnormalities of sarcotubular
organization may lead to the accumulation of proteins and
induce the unfolded protein response. Further investigation is
required to definitively identify the mechanism(s) by which
myotubularin deficiency impairs satellite cell survival.
Because of the deficiency of a single, ubiquitously ex-
pressed enzyme that has been modeled in several animal
systems, XLMTM is a disease with excellent potential for the
development of successful treatment strategies. Significant
limitations to the development or identification of potentially
useful agents include the lack of a high-throughput in vitro
assay on which new treatments could be tested and the
difficulty in generating sufficient animals for preclinical trials
on a rapid time scale. Although the relationship between the
increased apoptosis and slowed proliferation in Mtm14
cells and the progression of disease in Mtm14 animals
remains unclear, these cellular phenotypes represent repro-
ducible phenotypes that can easily be tested in a high-
throughput manner. The usefulness of myoblast cultures in
evaluating novel treatment strategies will be studied as our
laboratory continues to test novel agents in Mtm14 mice.
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